Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART19.1 in Relapsed or Refractory CD19 Positive B Cell Malignancies
NCT03853616Phase 1Active, not recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Nov 2018
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of zorpocabtagene autoleucel in acute lymphoblastic leukemia (ALL), B cell lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Miltenyi Biomedicine GmbH. Started Nov 2018; status: active, not recruiting.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03853616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853616.